Novo Nordisk’s $10B Bid Beats Pfizer in Obesity Drug Battle
The bidding war for obesity drugmaker Metsera just escalated dramatically. Novo Nordisk’s new $10 billion offer beats Pfizer’s revised $8.1 billion proposal, with Metsera calling the Danish bid “superior” and potentially ending Pfizer’s acquisition plans.











































